2019 WM Foundation Canada (WMFC) Seminar with Patients
WM Foundation Canada (WMFC)
Jewish General Hospital
Montreal, QC, Canada
November 7, 2019
Steven P. Treon MD, PhD, FACP, FRCP - Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute
In this video, Dr. Steven P. Treon speaks to a Montreal patient group providing updates on the genomics and latest treatment options for Waldenstrom's macroglobulinemia.
No slides available
Breaking News from the WM Front
Steven Treon, MD, PhD – Dana Farber Cancer Institute, 2019 Ed Forum
Explains why complete responses are so uncommon in WM, even with targeted therapy, what are the WM-centric toxicities with commonly used therapies, how pro-survival signaling of WM cells is driven by mutated MYD88 in WM, how CXCR4 mutations permit ongoing pro-survival signaling of Wm cells by CXCL12 and makes CXCR4 resistant to ibrutinib and the impact of CXCR4 on WM response and progression free survival (PFS). Reviews studies with ibrutinib, venetoclax, a combination of both drugs, zanubrutinib, acalabrutinib, and incorporating other novel treatments to eradicate residual or resistant disease. Also explains what the knowledge gaps are for developing more effective treatments for patients with WM without MYD88 mutations, the knowledge gaps for treating Bing Neel Syndrome, and treatment outcomes of WM-related peripheral neuropathy.
WM: Genomic & Treatment Advances
Zachary Hunter, PhD, Guang Yang, PhD, Steve Treon, MD, PhD – Dana Farber Cancer Institute, 2018 Ed Forum
Three researchers discuss how MYD88 and CXCR4 mutations are common in WM with MYD88 activating BTK and HCK in WM cells, both targets of ibrutinib. Ibrutinib produces high response rates and durable responses in relapsed and refractory WM. No complete responses. Mutated CXCR4, aberrant IRAK and BCL2 signaling contribute to intrinsic resistance against ibrutinib. Multiple BTK mutations are common with acquired ibrutinib resistance and trigger ERK1/2 survival signaling. Novel strategies to overcome intrinsic and acquired resistance to ibrutinib, including targeting CXCR4, ERK, IRAK, and BCL2 signaling.
New Insights into the Biology & Therapy of WM
Steven Treon, MD, PhD – Dana-Farber Cancer Institute, 2017 Ed Forum
Discusses manifestations of WM, side effects, genomics, treatment options, upfront treatment and relapsed/refractory treatment approaches
Translating Genomic Findings into New Treatment Opportunities for WM
Reviews WM-centric toxicities with commonly used therapies and discusses new directions in WM based on the MYD88 L265P somatic mutation in WM
IWMF Funding of Landmark Discoveries in WM and how Continued Funding is Critical for Future Management of the Disease
Steven P. Treon, MD, PhD – Dana Farber Cancer Institute, Boston, 2015 Ed Forum
Dr. Treon discusses his interest in WM and WM research, focusing on the whole genome sequencing research supported by the IWMF that helped make the critical discoveries of the MYD88 and CXCR4 mutations. He also mentions that continued funding of WM research is critical to future success in managing the disease.
No slides available
Targeted Therapies for WM
Steven Treon, MD, PhD - Dana Farber Cancer Institute, 2015 Ed Forum
Explains the WM-centric toxicities with commonly used therapies and new treatment directions in WM, including MYD88 L265P mutation and the MYD88 L265P signal pathway, Ibrutinib studies and its effect on side effects and survival, WHIM-like CXCR4 C-tail mutations in WM, unmutated MYD88 disease in WM, Idelalisib, clinical trial of ABT-199 (BCL2 inhibitor) in relapsed/refractory WM, resistance to Ibrutinib, and Ixazomib clinical trial
Advances in the Management of WM Revealed by Whole Genome Sequencing (Genomic Based Treatment Advances in WM)
Steven Treon, MD, PhD - Dana Farber Cancer Institute, 2014 Ed Forum
Discusses the NCCN options for treatment of WM, WM-centric toxicities with commonly used therapies, MYD88 L265P in WM /IgM MGUS, MYD88 L265P Signal Pathway and Ibrutinib (inhibitor of BTK), and Idelalisib (inhibitor of P13K-delta)
Improving Patient Outcomes through Discovery: WM - Dr. Treon presented details of past and ongoing research and discoveries (many of which occurred at the Bing Center) with regard to WM treatments and pointed toward what lies ahead as we look to the future of WM.
Steven Treon, MD, PhD, is the Director of the Bing Center for Waldenstrom's Macroglobulinemia at Dana-Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group.
Improving Patient Outcomes through Discovery: Waldenstrom's Macroglobulinemia (Chinese)
通過發現改善患者的治療效果：西醫-Treon博士介紹了有關西醫治療的過去和正在進行的研究和發現（其中許多發生在必應中心）的詳細信息，並指出了我們對西醫未來的展望。 史蒂芬·特雷恩（Steven Treon）博士是達納·法伯癌症研究所（DFCI）Waldenstrom巨球蛋白血症的Bing中心主任，哈佛醫學院的醫學教授，WM臨床試驗小組主席。
Improving Patient Outcomes through Discovery: Waldenstrom's Macroglobulinemia (French)
Amélioration des résultats pour les patients grâce à la découverte: MW - Le Dr Treon a présenté des détails sur les recherches et découvertes passées et en cours (dont beaucoup ont eu lieu au Centre Bing) en ce qui concerne les traitements de la MW et a souligné ce qui nous attend alors que nous envisageons l'avenir de la MW. Steven Treon, MD, PhD, est le directeur du Bing Center for Waldenstrom's Macroglobulinemia au Dana-Farber Cancer Institute (DFCI), professeur de médecine à la Harvard Medical School et président du WM Clinical Trials Group.
Improving Patient Outcomes through Discovery: Waldenstrom's Macroglobulinemia (Spanish)
Mejorar los resultados de los pacientes a través del descubrimiento: WM: el Dr. Treon presentó detalles de investigaciones y descubrimientos pasados y en curso (muchos de los cuales ocurrieron en el Bing Center) con respecto a los tratamientos de WM y señaló lo que está por venir mientras miramos hacia el futuro de WM. Steven Treon, MD, PhD, es el director del Bing Center for Waldenstrom's Macroglobulinemia en Dana-Farber Cancer Institute (DFCI), profesor de medicina en Harvard Medical School y presidente del WM Clinical Trials Group.